Prostate cancer Screening and Evaluation
A trusted resource for patients and providers exploring modern options for early detection.
Common Patient Questions
Early Checks
An elevated PSA is quite common and does not always indicate cancer. It can often be caused by minor inflammation or a naturally large prostate. We use these results as a helpful starting point to decide if detailed imaging is needed to ensure you stay healthy and informed.
Latest Tests
Innovative blood and urine tests can now provide deeper insights into your personal risk level. These advanced tools help us determine if further steps are truly necessary, allowing many men to avoid biopsies entirely.
Detailed Scans
A prostate MRI acts like a clear window that allows us to see the internal details of your health without surgery. By mapping any areas of concern with high precision, we can focus our attention exactly where it is needed. This modern approach ensures your care plan is based on accurate data.
Your Procedure
Modern techniques are designed to keep you relaxed and comfortable throughout the brief procedure. With local numbing and conscious sedation the process is efficient, and you can typically return to your normal daily routine by the very next morning.
Chad Ellimoottil, MD
ABOUT THE DOCTOR
Board-Certified Urologist
Associate Professor of Urology, University of Michigan
Division Chief, Men’s Health and Reconstruction
Dr. Chad Ellimoottil is a board-certified urologist at the University of Michigan who specializes in prostate cancer detection and advanced prostate biopsy techniques. He earned his undergraduate degree from Northwestern University, his medical degree from Loyola University Chicago Stritch School of Medicine, and completed his urology residency at Loyola University Medical Center. He also holds a master’s degree from the University of Michigan. Dr. Ellimoottil has been a faculty member at the University of Michigan for more than a decade and currently serves as Division Chief of Men’s Health and Reconstruction in the University of Michigan Department of Urology.
Dr. Ellimoottil’s clinical practice focuses on helping men understand and evaluate elevated PSA levels, abnormal prostate MRI findings, and concerns about prostate cancer. He has particular expertise in transperineal fusion biopsy, a modern prostate biopsy approach that uses MRI guidance to more precisely target suspicious areas of the prostate while reducing some of the risks associated with traditional biopsy methods.
In addition to caring for patients, Dr. Ellimoottil is an active researcher and educator. He has authored or co-authored more than 160 peer-reviewed journal articles and has contributed to multiple federally funded R01-level research grants. His academic work includes studies related to MRI/ultrasound transperineal fusion biopsy, patient experience with biopsy, and ways to improve the accuracy and safety of prostate cancer detection. He has helped teach advanced prostate biopsy techniques nationally and has served as a peer reviewer for the American Urological Association’s Early Detection of Prostate Cancer Guidelines.
Dr. Ellimoottil has been recognized for both patient care and academic excellence. During his residency, he received the Magis Star Award for excellent patient care at Loyola University. At the University of Michigan, he received the “Making a Difference” Award, which recognizes meaningful contributions to patients, colleagues, and the health system. He is also a co-inventor on a patented photoacoustic needle imaging probe designed for in vivo biopsy, reflecting his broader interest in improving how physicians identify and sample concerning areas in the prostate.
Dr. Ellimoottil’s goal is to make prostate cancer evaluation clear, accurate, and less intimidating for patients. He helps patients understand their PSA, MRI results, biopsy options, and cancer risk so they can make informed decisions with confidence.